News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Cathy Eng: Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer
Cathy Eng/X
Apr 5, 2025, 05:21

Cathy Eng: Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer

Cathy Eng, VICC Associate Director, Strategic Relations and Research Partnerships at Vanderbilt-Ingram Cancer, posted on X about recent paper she and colleagues co-authored:

“Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.”

Authors: Cathy Eng, Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, Elena Elez, Takayuki Yoshino, Alberto Sobrero, James Yao, Pilar Garcia-Alfonso, Judit Kocsis, Antonio Cubillo Gracian, Andrea Sartore-Bianchi, Taroh Satoh, Violaine Randrian, Jiri Tomasek, Geoff Chong, Zhao Yang, Ferdinand Guevara, William Schelman, Rajash Pallai, Josep Tabernero

Cathy Eng: Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer

Alberto Sobrero Arvind Dasari cancer Cathy Eng colorectal cancer Elena Elez Ferdinand Guevara FRESCO-2 Fruquintinib James Yao Josep Tabernero OncoDaily Oncology Rajash Pallai Rocio Garcia-Carbonero Sara Lonardi Takayuki Yoshino William Schelman Zhao Yang
Special Coverage
Blog
Apr 5, 2025, 05:21
Cathy Eng: Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer
Blog
Apr 5, 2025, 05:18
Guillermo J. Ruiz-Argüelles: México was present in EBMT meeting in Florence
Opinion
Apr 5, 2025, 05:13
Abstract Submissions for the 22nd SIO International Conference are now open
Blog
Apr 5, 2025, 05:00
Welcoming Alastair Lamb to Barts Cancer Institute
Blog
Apr 5, 2025, 04:50
The Mark Foundation for Cancer Research's Scientific Symposium 2025
Blog
Apr 5, 2025, 02:56
Did you know ALK Positive can help you gain access to world-leading specialists - at no charge?
Blog
Apr 4, 2025, 20:41
Michael Sapienza: Colorectal Cancer Alliance is hiring a VP of Data Intelligence and Technology
Science
Apr 4, 2025, 20:29
Gaëlle Saint-Hilary: Benefit-risk assessment of ivosidenib vs. placebo in mIDH1 cholangiocarcinoma
Blog
Apr 4, 2025, 20:12
David Planchard: A pleasure to discuss diagnostic and therapeutic advances in EGFR lung patients in Cannes
Science
Apr 4, 2025, 19:52
Paolo Bossi: Immunotherapy plus cetuximab in advanced/metastatic cutaneous squamous cell carcinoma
Blog
Apr 4, 2025, 19:34
Matthew Kurian: The barriers to AI adoption in oncology
Blog
Apr 4, 2025, 19:19
Michaela Cada: Proud to be part of the SickKids family for 20 years